Linear growth in thalassemic children treated with intensive chelation therapy. A longitudinal study

Area of Science:

• Pediatric Hematology
• Growth and Development
• Thalassemia Management

Background:

• Beta-thalassemia major is a severe genetic blood disorder requiring lifelong treatment.
• Growth retardation is a common complication in children with beta-thalassemia major.
• Effective chelation therapy is crucial for managing iron overload and improving outcomes.

Purpose of the Study:

• To investigate the impact of a defined treatment schedule on the linear growth of children with beta-thalassemia major.
• To assess the relationship between chelation therapy compliance and final adult stature.
• To evaluate the effectiveness of desferrioxamine mesylate in promoting growth in this patient population.

Main Methods:

• A longitudinal study of 10 children (6 girls, 4 boys) with beta-thalassemia major.
• Treatment included regular blood transfusions and subcutaneous desferrioxamine mesylate (40 mg/kg/day, 5 days/week) for 7 years.
• Patients were monitored from diagnosis until reaching adult bone age.

Main Results:

• Growth retardation was observed in 3 out of 4 boys and 1 out of 6 girls before age 10.
• Growth failure became more pronounced between ages 10-15, with improvement after age 15.
• Eight out of 10 patients achieved normal adult stature; poor compliance was noted in the two with short stature.

Conclusions:

• Intensive chelation therapy with desferrioxamine mesylate positively impacts linear growth in children with beta-thalassemia major.
• Adherence to chelation therapy is critical for achieving optimal growth outcomes.
• Early and consistent treatment can help patients reach their target height despite the challenges of beta-thalassemia major.